Absci reports positive Phase 1 data for ABS-201

• Absci Corp (NASDAQ:ABSI) reported positive interim Phase 1 data for ABS-201 in healthy volunteers.
• The study showed the drug was generally well tolerated, with no serious adverse events across dosing cohorts.
• The company is advancing to multiple ascending dose studies with key readouts expected in 2026 and 2027.

Absci Corp (NASDAQ:ABSI) reported positive interim Phase 1 data from the HEADLINE trial evaluating ABS-201, an investigational anti-PRLR antibody in development.

The study enrolled 32 healthy volunteers across four single ascending dose cohorts ranging from 150 mg to 1800 mg administered intravenously.

ABS-201 was generally well tolerated, with no serious adverse events reported and most treatment-emergent adverse events classified as mild across all dose groups.

The drug showed an estimated half-life of at least 65 days, supporting potential dosing schedules of two to three administrations over a six-month period.

Absci said it has begun the multiple ascending dose phase in participants with androgenetic alopecia, with interim proof-of-concept data expected in the second half of 2026 and further clinical updates extending into 2027.